Initiation of next-generation diabetes treatment development
[by Yu, Suin] Kangstem Biotech disclosed on August 1 that it has entered into a memorandum of understanding (MOU) with Optipharm to initiate joint research focused on pancreatic 에볼루션 바카라 사이트 organoids, aiming to develop next-generation diabetes treatments.
By integrating stem cell-derived pancreatic 에볼루션 바카라 사이트 organoid production technology with 에볼루션 바카라 사이트 isolation and xenotransplantation technologies utilizing transgenic pigs, the two companies aim to evaluate the therapeutic efficacy of pancreatic 에볼루션 바카라 사이트 organoids for insulin-dependent diabetes in medium- to large-sized animal models, including primates. This collaboration will actively pursue research and development (R&D) efforts directed toward the commercialization of the treatment.
Drawing on its extensive experience in stem cell research and cell therapy development, Kangstem Biotech has established a proprietary platform technology for generating pancreatic 에볼루션 바카라 사이트 organoids from human-induced pluripotent stem cells (iPSCs). According to the company, it has successfully produced organoids exhibiting superior insulin secretion capabilities compared to conventional methods. When transplanted into diabetic mouse models, these organoids yielded preliminary results indicating that blood glucose levels remained in a near-normal range.
Optipharm possesses outstanding expertise in the creation of transgenic pigs, as well as in 에볼루션 바카라 사이트 isolation and xenotransplantation technologies, and is at the forefront of research aimed at minimizing immunological rejection in transplantation procedures. Through this collaboration, both companies seek to harness their respective technological capabilities to develop next-generation diabetes therapies based on 에볼루션 바카라 사이트 transplantation, with emphasis on ensuring safety and efficacy.
"By combining our organoid technology with the xenotransplantation platform, we aim to offer new treatment options for patients with diabetes," expressed Na Jong-cheon, president of Kangstem Biotech. "The integration of our transgenic pig-based transplantation technology with Kangstem Biotech's stem cell-derived islet organoid technology is expected to yield competitive solutions in the global diabetes treatment market," stated Kim Hyun-il, CEO of Optipharm.
The global diabetes treatment market is projected to reach approximately USD 70 billion (approximately KRW 97 trillion) in 2025, reflecting a sharp rise in demand for fundamental treatments such as 에볼루션 바카라 사이트 transplantation. Building on this business agreement as a starting point, the two companies intend to establish a mass production platform for pancreatic 에볼루션 바카라 사이트 organoids and develop a xenotransplantation model. They further plan to progressively advance non-clinical and clinical research efforts, thereby accelerating the development and commercialization of innovative treatments for metabolic disorders, including diabetes.